pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 13·1 min read
save

Dementia prevention trial in Latin America replicates earlier promising results with culturally tailored risk-reduction program

Jul 13, 2026·read at STAT ↗Positive readoutPositive

A new dementia prevention study presented at the Alzheimer’s Association International Conference showed results that mirror earlier findings, reinforcing the value of structured risk‑reduction programs.

The trial focused on lifestyle factors known to influence dementia risk, such as nutrition, sleep quality, cardiovascular health and physical activity, and adapted the interventions to local cultural contexts.

Researchers highlighted the study as a "landmark" effort, noting that the replicated outcomes suggest the approach could be scalable across diverse populations.

The conference, which hosted over 10,000 attendees from more than 100 countries, provided a platform for sharing these findings with the broader scientific and public‑health community.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Dementia study replicates promising outcomes following risk-reduction strategies”

read at STAT ↗
580 words · retrieved Jul 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ROCHE
topics
Alzheimer's Disease7Cardiology3CRISPR/Cas9Oncology

related stories

  • 5d agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Sep 10Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneFierce Biotech
  • Jul 12STAT+: Tau in the spotlight at Alzheimer’s conferenceSTAT
  • Dec 23Fierce Biotech Layoff Tracker 2026: Caribou cuts staff, halts pipeline; Foghorn reduces workforce by 40%Fierce Biotech
  • Jul 24Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechBioSpace